RT Journal Article
SR Electronic
T1 Preclinical in vitro and in vivo results of the new silk vista flow diverter with P8RI coating
JF Journal of NeuroInterventional Surgery
JO J NeuroIntervent Surg
FD BMJ Publishing Group Ltd.
SP jnis-2024-021694
DO 10.1136/jnis-2024-021694
A1 Cortese, Jonathan
A1 Forestier, Géraud
A1 Bardet, Sylvia M
A1 Perrin, Marie-Laure
A1 Baudouin, Maxime
A1 Belgacem, Alexis
A1 Chauvet, Romain
A1 Ratsimbazafy, Voahirana
A1 Sasselina, Gregory
A1 Chandellier, Daphnée
A1 Mounier, Jérémy
A1 Couquet, Claude
A1 Bosselut, Florence
A1 Spelle, Laurent
A1 Mounayer, Charbel
A1 Terro, Faraj
A1 Rouchaud, Aymeric
YR 2024
UL http://jnis.bmj.com/content/early/2024/06/24/jnis-2024-021694.abstract
AB Background Flow diverting stents (FDS) have transformed the treatment of intracranial aneurysms; however, their metallic structure associated with their intra-luminal positioning hamper angiographic and clinical outcomes. Therefore, there is a need to develop FDS with optimized surfaces that reduce thrombogenicity while promoting the healing process and endothelialization.Methods P8RI, a peptide mimicking the CD31 protein, was previously developed and grafted onto Silk Vista (SV) FDS. P8RI-SV and bare-SV were used in vitro in a blood loop model to test their hemocompatibility using human whole blood and in vivo using the rabbit elastase model for optical coherence tomography (OCT) comparisons of neointimal formation at day 5 and day 28.Results After blood loop incubation, P8RI-SV showed significant reduction in fibrin binding (p=0.004) and platelet adhesion (p=0.041) compared with bare-SV. Similarly, derivative markers measured in blood, thromboxane B2 (platelet activation) and Thrombin-Antithrombin III complexes (coagulation activation), were also significantly reduced in the P8RI-SV group (both p=0.002). In vivo, complete or near-complete occlusion was reached in all aneurysms (n=6) at day 28. Excellent rate of stent-coverage ratio was obtained at day 5 (89.3% (79.1%–98.7%)) comparable to the observation at day 28 (91.8% (79.1%–100%); p=0.44). These rates were significantly higher compared with bare-SV at day 5 (77.8% (58.3%–86.8%); p<0.001) and at day 28 (67.7% (52.6%–88.9%); p<0.0001).Conclusion In vitro results confirm enhanced hemocompatibility with a significant anti-thrombotic effect of the P8RI-SV. In vivo results provide evidence of rapid neo-intimal growth reaching near-complete tissue healing as early as day 5 in a rabbit model.Data may be obtained from a third party and are not publicly available.